Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Revenue does not include sales unless those sales are paid for, so why would revenue be higher? Sales are made and the customer has a period agreed upon in the sales contract (30, 45, 60 days, etc.) to pay the company. Only then the sales amounts included in the revenues reported. If $2M in sales to are recorded in a quarter, but payments of only $1M is received during the quarter, then $1M is recorded for revenue and accounts receivable for the quarter.
Regarding the paragraph about the customer who has not yet paid, that's always a risk for any company, and that's why we have the courts to resolve these disputes. Amarantus had multiple lawsuits for unpaid bills, so now GC is on the other end of that issue.
I'm okay with releasing unaudited financials, as this is allowed per SEC rules and stated in the filing. There was a shareholder on Twitter urging GC to post the filings and amend any changes later. Perhaps that's what he decided to do, removing the urgency of the auditors to complete their review this week. We don't know what's going on with the auditor firms that might have caused another delay. I don't automatically believe the company is trying to deceive shareholders when a glitch occur. Some do. Different strokes. Both the CEO and CFO are legally on the hook for the accuracy of this unaudited filing. I expect we will see a fully audited update in the near term.
The company was reporting sales in the press releases, not revenues, which is why the numbers don't seem to align. The 10-Q is reporting revenues.
Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021
https://investor.todosmedical.com/news-events/press-releases/detail/105/todos-medical-announces-7-2m-in-sales-for-february-2021-a
During my initial review of the 10-Q, I realize the charts I have previously posted had a significant error. I was reporting sales but calling it revenue on the charts. Sales does not equal revenue. While some sales during a period may result in revenues, sales not yet paid for would be added to Accounts Receivable, which is an asset of the company, not a revenue category.
I realized this error when reviewing Q1 2021 revenue figures in the report that didn't match what I had previously reported. I will update the charts accordingly and repost, changing from monthly to quarterly totals to align with how the company is currently reporting sales and revenues.
Todos Medical 10-Q filed
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001493152-21-015003/0001493152-21-015003.pdf
Let the gnashing of teeth and the feeding frenzy begin.
Regarding the author, Chris Sandburg, here is what I found on the web site. He writes articles on many biotech companies, including NASDAQ and NYSE-listed biotechs. I believe this tends to give him a bit more legitimacy than someone who only writes about OTC penny stocks. Just my opinion.
https://insiderfinancial.com/author/chris-sandburg/
No guess on the day. Doesn't matter to me as long as they are released this week. I expect to see Form 4 updates after the financials, not before. I'm still not convinced there was insider buying the last few weeks. The site you posted seemed to indicate that, but other sites did not.
There is a disclaimer at the end of the article, but it doesn't provide any info on the author's ownership status.
Disclosure: Insider Financial and its owners do not have a position in the stocks posted and have posted this article for free without editorial input. This article was written by a guest contributor and solely reflects his opinions.
There is another disclaimer for the site that goes into much greater detail at this link:
https://insiderfinancial.com/disclaimer/
I'm not trying to convince you of anything. It makes no difference to me if you invest or not, if you pass on this article or not. Maybe he responds, maybe he doesn't. While I agree we don't know this person and might be suspect of his response (if any), I would assume if he does state he is a shareholder, then why would that be a lie? Yes, it could indicate bias in the article, but being a shareholder doesn't automatically infer bias. The article seems well researched with plenty of links to the companies mentioned and is clearly the author's opinion. I believe the article gives a fair account of current events and there is enough uncertainty stated to indicate this is definitely NOT a sure thing for Todos, or even for Pfizer. No one knows with any certainty how this story will unfold.
To each his own. Every one of us has motives. My motivation is to make money with this investment, but I won't go as far as lying about the company, nor will I pump the stock to get a better price if I'm looking to exit. I continue to tell those who read my posts to invest only what you can afford to lose in the penny stock realm. This is still a high risk investment. Anyone who reads this article and decides they can get rich quick by investing all of their money in Todos is a gambler and not an investor and may live to regret that decision. There's still a good deal of uncertainty here, but in my opinion things are looking better than at any time in the past regarding the company's potential, with is not reflected in the share price. Dilution with fundraising has hurt us there. Let's see what the financial update reveals.
Financials should be out this week according to GC's tweet. Then I expect to start seeing Form 4's filed with the SEC from insider buying.
I emailed Chris Sandburg asking if he was invested in Todos. If I get a reply I will post it here.
I noticed the title of the article changed after the article was published.
Initially it was:
Pfizer Takes On All Coronaviruse
Changed to:
Todos Medical (TOMDF) with a $22 Million Market Cap Taking on Pharma Giant Pfizer for COVID-19 Antiviral
Also, in the article text the market cap of Todos is $16M and in the new title it is $22M, but the text remains unchanged. Share price was rising during the interim.
Todos Medical (TOMDF) with a $22 Million Market Cap Taking on Pharma Giant Pfizer for COVID-19 Antiviral
Insider Financial
OTC Markets Stock News
June 19, 2021
https://insiderfinancial.com/pfizer-takes-on-all-coronaviruses/181664/
Great article. Send this to every investor you know and let's get the word out to those who have never heard of Todos Medical.
Outstanding Shares Update - 6/18/21
https://www.otcmarkets.com/stock/tomdf/security
The mental process used in forming this "confirmation" is indeed lacking. I found the article, as I have found others posted here, by occasionally reading other investor boards for both AMBS and TOMDF. If you review my posts, I have occasionally mentioned posts found on other boards so there is already precedent for this behavior. I'll leave it to you to find this article mentioned on other boards, if that isn't expecting too much.
I don't communicate with GC, I don't work for GC, and I don't get paid for posting here or for responses. And my name is neither Joe or Joey. Wrong at every turn. I am an investor in Todos (700K+ shares) who moderates this board, and nothing more.
Here's something that may help in future deductive reasoning and conclusions. Amazon has a good price.
Gerald Commissiong of Todos Medical: 5 Things I Wish Someone Told Me Before I Became a CEO
An Interview With Charlie Katz
AUTHORITY MAGAZINE - June 13, 2021
https://medium.com/authority-magazine/gerald-commissiong-of-todos-medical-5-things-i-wish-someone-told-me-before-i-became-a-ceo-4713037264c8
GC quoted in June 10, 2021 WIJA news story.
https://wjla.com/news/coronavirus-vaccine/white-house-exploring-tentative-plans-to-resume-international-travel
White House exploring tentative plans to resume international travel
WASHINGTON (Sinclair Broadcast Group) — International travel is making a comeback. Dozens of countries are reopening their borders to U.S. tourists and the Biden administration is formulating plans to restart travel with some of America's closest partners.
The world is starting to reopen. That's sparking excitement among stir-crazy travelers and cautious optimism from public health officials who are confident in COVID-19 vaccines but remain concerned about virus variants.
"It is still risky," said Dr. Lin Chen director of the Travel Medicine Center at Mount Auburn. "The risk is just far lower for the vaccinated people."
With nearly 64% of U.S. adults partially vaccinated, the White House announced plans to reopen travel with some of America's closest partners. This week, several working groups made up of public health experts started exploring when and how to resume non-essential travel with Canada, Mexico, the European Union and the United Kingdom.
"The point of these working groups is to share data and set out both milestones and criteria to enable a reopening of travel between our two countries as swiftly as possible, consistent with public health guidance," National Security Adviser Jake Sullivan told reporters Wednesday, referring to the U.K. and E.U. groups.
The effort is being led by the White House Covid-19 Response Team and the National Security Council with representatives from the Centers for Disease Control and Prevention and the Departments of State, Homeland Security, Health and Human Services, and Transportation, according to reports.
The White House signaled that it's not ready to lift restrictions on international non-essential travel yet or announce a timeline to allow foreign visitors into the United States. "At the end of the day this is a process being driven by science and public health guidance," Sullivan said. The United States still has COVID-19 travel bans on the E.U., the U.K., Ireland, China, Brazil, South Africa, India and Iran. U.S. land borders have also been closed to Canadian and Mexican travelers since March 2020.
The U.S. Travel Association celebrated the announcement as "an important step forward in our national recovery from the pandemic."
Even with the United States closed to most foreign tourists, the world is starting to open up again. France and Spain announced they would accept vaccinated American tourists this summer. Many other popular destinations are welcoming travelers with proof of vaccination, a positive serological test for antibodies or a negative COVID test.
Cruises are launching this summer, with some requiring vaccines and others not. Royal Caribbean announced it would sail eight ships from ports in Florida and Texas to international destinations beginning in July. Norwegian and Carnival are also resuming trips.
At the same time, pressure has been growing for governments in countries that are still closed to lessen travel restrictions, particularly as more countries ramp up vaccine distribution.
This week top airline and airport executives in the U.S. and U.K. urged both governments' leaders to establish a travel corridor and lift the mutual travel bans. Both the U.S. and U.K. have vaccinated over 60% of their population. "These are the poster children of good vaccination programs," said John Holland-Kaye, CEO of London's Heathrow Airport at a Monday press conference. "There needs to be a prize for that."
Yet, the emergence of new, highly transmissible variants has led some to question the risks and benefits of resuming international travel.
On Thursday, the World Health Organization urged Europeans to travel "responsibly" over the summer holiday, warning the continent was "by no means out of danger" despite increased vaccinations and lower case counts.
Average daily new cases in the U.K. have spiked 68% over the last week, driven by the Delta variant, first detected in India.
The Delta variant has spread quickly among children and young adults. According to the U.K. health secretary, it is causing 91% of Britain's new COVID cases and has threatened to derail British Prime Minister Boris Johnson's plans to reopen the economy later this month.
Yet, preliminary data from the National Institutes of Health suggest two doses of the Pfizer and AstraZeneca vaccines are likely to provide protection against the Delta variant with minimal loss of efficacy. A single dose of either dramatically reduces efficacy.
Across the board, all the vaccines available in the United States have proven effective against all the variants of concern. Not only do they prevent serious illness in vaccinated people but studies show that they also limit transmission of the virus to others in rare cases of breakthrough infections. The lower risk of illness and transmission bodes well for vaccinated jet-setters and for public health generally.
"Vaccination is going to help us reopen the world," said Dr. Chen."I really see that as the major way of reopening travel."
Additionally, there are layered protections in place around international travel. Passengers are required to wear masks on flights. Anyone flying back to the United States must also present a negative COVID-19 test taken 72 hours before their return flight.
For those who are ready to travel abroad, experts say getting fully vaccinated is the first and most important step. After that, it's critical to understand the landscape before jumping on a plane.
"There's a chaotic mix of different requirements and they're rapidly changing," Dr. Henry Wu, an epidemiologist and director of the Emory TravelWell Center told reporters Thursday. That includes local mask mandates, vaccine requirements, tests and quarantines. "So, do your research and stay flexible."
Countries with high rates of vaccination and low case counts are the safest destination. Those experiencing surges of COVID-19 infections are not a good choice, Wu noted. Not only is the possibility of infection greater but travelers risk becoming a burden on a strained hospital system if they become sick or injured.
The State Department currently advises strongly against traveling to 38 countries. That number is down significantly from April when the State Department issued a widespread travel warning for more than 80% of countries due to COVID-19 infection rates.
The CDC's map of travel recommendations by destination shows much of the world in the "high" to "very high"-risk level for COVID-19.
Compared to lockdown, travel will always increase the risk of spreading the virus. But even with strict limitations in place, the risk of new variants entering the country is always possible. B.1.1.7, or the Alpha variant first detected in the U.K., now accounts for over two-thirds of new U.S. COVID cases. Around 10% of new cases are the highly transmissible P.1 or Gamma variant, that first emerged in Brazil, according to the CDC. The Delta variant, which is driving up cases in Western Europe, has been detected across the United States, making up 6% of new infections.
"The question we've got to ask ourselves is: is this something we can stop or is it inevitable?" said Gerald Commissiong, CEO of Todos Medical, Ltd., a diagnostics company focused on COVID-19 testing, screening and immune support.
By focusing on vaccinating as much of the population as possible, public health officials hope to get a baseline immunity to protect against emerging variants of concern. But it's a race against the emergence of variants in other parts of the world where vaccines are unavailable.
"At the end of the day, there's no denying the biological risk that some of these variants will overcome the vaccines," Commissiong noted. "If we don't help the world get vaccinated ... it's inevitable there's going to be a variant that makes all these vaccines useless."
On Wednesday, the Biden administration announced the U.S. would share 500 million doses of the Pfizer vaccine with low-income countries in Latin America, the Caribbean, Africa, Asia and parts of Oceania. Last month, the U.S. announced it would donate 80 million U.S. vaccines from its excess supply to COVAX, the worldwide vaccine initiative.
The contribution marks the largest single-country donation of vaccines during the pandemic. Beyond protecting millions of people against the virus, the widespread distribution of vaccines also serves U.S. national interests, the White House explained. "COVID-19 knows no borders," a senior White House official told reporters Thursday. "As long as this virus has a hold somewhere in the world, Americans are at risk."
In addition to vaccines, the development of antiviral drugs and therapeutics are also helping win the fight against COVID-19 and improving the prospects of the safe return of international travel. On Wednesday, Merck announced it would supply the U.S. government with 1.7 million doses of molnupiravir, an oral antiviral drug to treat outpatient cases of COVID-19, pending approval by the Food and Drug Administration.
I don't agree that the information you posted indicates insider trading. I have looked at several other insider trading tracking sites and they show no insider trading for Todos Medical. Also, no SEC Form 4's have been filed since January reporting purchases. Your entire hypothesis depends on an assumption for which there is no proof one way or the other.
I can understand why GC was ticked off. You are essentially claiming insiders are illegally buying shares and are manipulating the share price in order to do so by withholding the quarterly filing. Perhaps you haven't been watching the news, but Israel has been under multiple attacks by Hamas, including more attacks in the last 24 hours. GC stated in a tweet that this was the primary reason for the delay, as the CFO is based in Israel.
If your insider data is in fact accurate, it doesn't necessarily mean the activity is illegal. The SEC provides rules that allow legal insider trading. Insider trades could have been pre-planned or conducted in a way to meet these rules. The insider data you presented might be coincidental to the delay in financials, but it doesn't necessarily imply one has anything to do with the other. One can state opinion and list a lot of "facts" but that still doesn't point to conclusive evidence a crime was committed.
I think GC's response was typical of someone being accused of committing a crime. I'd likely respond in similar fashion, but not as polite.
Posting "factual information" that isn't observed on other insider trading sites tends to make me believe there is nothing to this claim. Just my two cents. I own 710K shares and would like to think that insiders are loading up on shares, but legally. We may see Form 4's show up in the near future. It could be Yozma buying shares in the secondary market. They would also be insiders and their purchases would have nothing to do with the delay in financials. It seems unlikely Yozma has access to the financial data about to be released, so their insider purchases would not violate SEC rules. Different rules would apply to company officers. Something to think about... what one person sees as illegal activity another can find a reasonable explanation for it.
Todos Medical presenting at 2021 LD Micro Invitational XI on Thursday, June 10, 2021 from 6:00-6:25 PM EDT.
https://ldmicrojune2021.mysequire.com
Expecting financials and possibly other news to be released prior to this presentation.
Supporting GC, how? By buying shares in Todos, even after losing a large sum in a previous penny stock company with GC at the helm? Or by continuing to hold those shares, even as the dilution continues, because of a belief in the company, not GC?
Hard to know if one is supporting GC or not when posting of selling their Todos shares and then 6 weeks later posting as a shareholder again. The support of GC and Todos by continuing as a shareholder when one believes him completely incompetent is commendable.
Life might be more enjoyable if one finds an investment they believe in, where they can be enthusiastic and happy, not where they are miserable by investing again in a high risk penny stock with the same CEO and expecting different results.
Not trying to be condescending here, just realistic. If I ever reach the point where I've lost faith in the CEO and company outlook I will sell and move on. I'll post that I'm out and you won't see another post weeks later claiming I'm still a shareholder.
Expecting significant updates this week.
Expecting news and earnings report this week. Looking forward to finding out what has transpired during this quiet period.
Care to shed light on these contradictory posts?
Posted on 4/15:
You will be glad to hear I took your advise and sold my interest in TOMDF.
Posted on 5/31:
And yes I am, regretably, a shareholder. Didn't learn my lesson from ambs. All the posts about maybe he learned something from his previous mistakes sucked me in. What he learned was there is a sucker born evry day and some times twice.
About as many who believe in that pump-n-dump WOGI the the shysters promoting on that board.
Good info, but if that is true, why did he file a 13G for passive ownership with no intent to exercise control or voting of his shares? He could have filed a 13D indicating he intended to exercise control to try to influence the direction of the company.
The concern I have and I assume is in many investors minds is who did Gerald possibly piss off with the Amarantus debacle that is now working against the Todos share price? We have seen data indicating someone is actively shorting the stock. With revenues growing as they are, we all expected the share price to be well north of 4 cents by now. Share dilution may be the only factor involved, but my gut tells me there's another factor weighing negatively on the share price, so perhaps what you have posted is a factor.
I'm holding my shares, but wondering how long I will be sitting on dead money and lost opportunity cost for the amount I have invested in Todos. Doing well with my other investments, but still significantly in the red with Todos.
If you're implying I have done little DD on Robb, then you are correct. I have never stated otherwise. I was not even aware he owned Provista until it was posted on this board.
Schedule 13G Definition from Investopedia
There's an excellent one-minute video available using the link that provides a brief overview of Schedules 13D and 13G and it's worth watching to fully understand when these forms are used. I cannot link the video directly but it's in the middle of the article at the link below.
https://www.investopedia.com/terms/s/schedule13g.asp
What Is Schedule 13G?
The Securities and Exchange Commission (SEC) Schedule 13G form is an alternative filing for the Schedule 13D form and is used to report a party's ownership of stock which exceeds 5% of a company's total stock issue. Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements. Schedule 13G can be filed in lieu of the SEC Schedule 13D form as long as the filer meets one of several exemptions.
Both Schedule 13D and Schedule 13G forms are referred to as "beneficial ownership reports." According to the SEC, a beneficial owner is anyone directly or indirectly shares voting power or investment power. These forms are intended to provide information about individuals who have significant holdings in publicly-traded companies and thus, allow for other investors and other interested parties to make informed decisions about their own investments. The ownership of over 5% of a publicly-traded stock is considered significant ownership and reporting this to the public is a requirement.
KEY TAKEAWAYS
• Securities and Exchange Commission (SEC) Schedule 13G form is used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
• Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
• Schedule 13G can be filed in lieu of the SEC Schedule 13D form as long as the filer meets one of several exemptions.
Investors and any other interested parties can view the Schedule 13G forms of any publicly-traded company through the SEC's EDGAR system.
Understanding Schedule 13G
There are several exemptions that permit a filer to file form Schedule 13G instead of Schedule 13D. Institutional investors can file a Schedule 13G if they acquired securities while doing normal business and they have no intention of influencing control of the issuer. Individuals who are not institutional investors can file a Schedule 13G if they have not acquired the security with the intent of influencing control over the issuer and are not directly or indirectly the beneficial owner of 20% or more of the security. Under Section 13(d)(6)(A) or (B) of the Securities Exchange Act of 1934, there are additional exemptions for investors. An investor may also be exempt if their beneficial ownership was acquired before December 22, 1970.
There are several filing deadlines for Schedule 13G. For institutional investors, they are required to file within 45 days of the end of the year in which they finish above 5%, or within 10 days of first finishing a month above 10% if the initial filing has not yet been completed. Passive investors are required to file within 10 days of acquiring 5% or more of a security. Finally, exempt investors (as defined by Section 13(d)(6)(A) or (B) of the Securities Exchange Act of 1934) must file within 45 days of the end of the year in which they become obligated to file.
Any changes to the information contained in a Schedule 13G form must be amended through additional reporting. Institutional investors are required to file an amendment to report any changes within 45 days of the end of the year or within 10 days of first finishing a month above 10% and then within 10 days of any month-end where the holder's ownership increases or decreases by 5% or more. Passive investors have similar requirements for reporting amendments.
The SEC can impose fines on individuals and/or companies for improperly filing Schedule 13G forms or failing to file them. Individuals can be cited if they fail to promptly report information about their holdings and transactions, and companies can be fined if they do not report that their employees have not properly filed any required forms. Even if it is inadvertent, the failure to timely file a required beneficial ownership report is a violation of the requirements set out under Sections 13(d), 13(g) and 16(a) of the Securities Exchange Act of 1934.
It is very important that fund managers and other investors are aware of their internal control policies and procedures. In order to settle improper filing claims with the SEC, individual investors have been forced to pay upwards of $150,000 in financial penalties. The SEC makes an effort to police these sorts of violations because these forms are intended to protect the public, keeping them aware of the trading activity of insiders and ultimately, preventing insider trading and other acts of stock manipulation.
There is no indication Robb Rill is selling. Schedule 13G is a statement of ownership. Form 4 is used to report sales, and that has not been filed.
Outstanding Shares Update - 5/7/21
https://www.otcmarkets.com/stock/tomdf/security
Schedule 13G Filing - Strategic Investment Holdings, LLC
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001493152-21-010725/0001493152-21-010725.pdf
He should be in Israel now, based on his Twitter post yesterday.